W Y Cheung1, P Kavan2, A Dolley3. 1. Section of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB. 2. Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC. 3. Taiho Pharma Canada Inc., Oakville, ON.
Abstract
Background: Quality of life (qol) is important for oncology patients, especially for those with late-stage disease. The present study was initiated to address the lack of published prospective data about the qol benefits of trifluridine/tipiracil (ftd/tpi) compared with best supportive care (bsc) in patients with refractory metastatic colorectal cancer (mcrc). Methods: This prospective, cross-sectional, non-interventional study used multidimensional validated scales to evaluate patient-reported qol in two study cohorts of patients and also to measure differences in mcrc-related symptoms and pain in a real-world clinical setting. Results: Our findings demonstrate that patients with refractory mcrc report better overall qol when treated with ftd/tpi than with bsc alone. In that population, statistically significant differences in mean qol measures favoured ftd/tpi over bsc for physical symptom distress, psychological distress, activity impairment, overall valuation of life, and symptomatology. The overall better qol for patients receiving ftd/tpi implies that treatment was well tolerated and was associated with a lower symptom burden. No significant differences for pain were observed between the groups. Conclusions: This study suggests that ftd/tpi is a well-tolerated option for the treatment of patients with refractory mcrc, showcasing the value of capturing real-world qol data in routine clinical practice. 2020 Multimed Inc.
Background: Quality of life (qol) is important for oncology patients, especially for those with late-stage disease. The present study was initiated to address the lack of published prospective data about the qol benefits of trifluridine/tipiracil (ftd/tpi) compared with best supportive care (bsc) in patients with refractory metastatic colorectal cancer (mcrc). Methods: This prospective, cross-sectional, non-interventional study used multidimensional validated scales to evaluate patient-reported qol in two study cohorts of patients and also to measure differences in mcrc-related symptoms and pain in a real-world clinical setting. Results: Our findings demonstrate that patients with refractory mcrc report better overall qol when treated with ftd/tpi than with bsc alone. In that population, statistically significant differences in mean qol measures favoured ftd/tpi over bsc for physical symptom distress, psychological distress, activity impairment, overall valuation of life, and symptomatology. The overall better qol for patients receiving ftd/tpi implies that treatment was well tolerated and was associated with a lower symptom burden. No significant differences for pain were observed between the groups. Conclusions: This study suggests that ftd/tpi is a well-tolerated option for the treatment of patients with refractory mcrc, showcasing the value of capturing real-world qol data in routine clinical practice. 2020 Multimed Inc.
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Matti Aapro; Florian Scotte; Thierry Bouillet; David Currow; Antonio Vigano Journal: Clin Colorectal Cancer Date: 2016-05-07 Impact factor: 4.481
Authors: S Ahmed; L Barbera; S J Bartlett; D G Bebb; M Brundage; S Bryan; W Y Cheung; N Coburn; T Crump; L Cuthbertson; D Howell; A F Klassen; S Leduc; M Li; N E Mayo; G McKinnon; R Olson; J Pink; J W Robinson; M J Santana; R Sawatzky; R S Moxam; S Sinclair; F Servidio-Italiano; W Temple Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Melanie Calvert; Derek Kyte; Rebecca Mercieca-Bebber; Anita Slade; An-Wen Chan; Madeleine T King; Amanda Hunn; Andrew Bottomley; Antoine Regnault; An-Wen Chan; Carolyn Ells; Daniel O'Connor; Dennis Revicki; Donald Patrick; Doug Altman; Ethan Basch; Galina Velikova; Gary Price; Heather Draper; Jane Blazeby; Jane Scott; Joanna Coast; Josephine Norquist; Julia Brown; Kirstie Haywood; Laura Lee Johnson; Lisa Campbell; Lori Frank; Maria von Hildebrand; Michael Brundage; Michael Palmer; Paul Kluetz; Richard Stephens; Robert M Golub; Sandra Mitchell; Trish Groves Journal: JAMA Date: 2018-02-06 Impact factor: 56.272
Authors: Milena Anatchkova; Sarah M Donelson; Anne M Skalicky; Colleen A McHorney; Dayo Jagun; Jennifer Whiteley Journal: J Patient Rep Outcomes Date: 2018-12-27
Authors: Wei Fang Dai; Claire de Oliveira; Scott Blommaert; Reka E Pataky; David Tran; Zeb Aurangzeb; Cynthia Kendell; Chris Folkins; Chandy Somayaji; Jeff Dowden; Winson Cheung; Erin Strumpf; Jaclyn M Beca; Carol McClure; Robin Urquhart; James Ted McDonald; Riaz Alvi; Donna Turner; Stuart Peacock; Avram Denburg; Rebecca E Mercer; Caroline Muñoz; Ambica Parmar; Mina Tadrous; Pam Takhar; Kelvin K W Chan Journal: Curr Oncol Date: 2022-03-17 Impact factor: 3.677